Search

Displaying results 7901 - 7910 of 10000 in total
  1. Drug

    Lexatumumab

    go.drugbank.com/drugs/DB06599
    Investigational

    Lexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb).

  2. Drug

    Apixaban

    go.drugbank.com/drugs/DB06605
    ApprovedInvestigational

    Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic … It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: ELIQUIS® 5 MG, MANTIXA® 5 TABLETAS RECUBIERTAS
  3. Drug

    Cutamesine

    go.drugbank.com/drugs/DB06618
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Amdoxovir

    go.drugbank.com/drugs/DB06619
    Investigational

    Synonyms: beta-D-2,6-Diaminopurine-dioxolaneCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  5. Drug

    ARG201

    go.drugbank.com/drugs/DB06621
    Experimental

    ARG201, a bovine-derived Type I collagen, aims to induce immune tolerance in patients with Diffuse Systemic Scleroderma (dcSSc). … This drug was investigated in the completed clinical trial NCT0000567 (Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma)

  6. Drug

    Vipadenant

    go.drugbank.com/drugs/DB06625
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  7. Drug

    Zibotentan

    go.drugbank.com/drugs/DB06629
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.

    Categories: Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: 4-AP, 4-Aminopyridine
  10. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia® … Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of

    Products: XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 4 ADET, XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET